Zim Laboratories' Q2 FY 2025-26 Quarterly Results

Result Summary

• Zim Laboratories Ltd reported a 23.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 2.9%.
• Its expenses for the quarter were up by 20.4% QoQ and 0.7% YoY.
• The net profit decreased 77.5% QoQ and decreased 117.6% YoY.
• The earnings per share (EPS) of Zim Laboratories Ltd declined at 0.09 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Zim Laboratories Ltd is a pharmaceutical company primarily engaged in the development and manufacture of drug delivery systems. The company's expertise lies in the formulation of complex generics and novel drug delivery systems, catering to various therapeutic areas. Zim Laboratories is known for its focus on improving drug delivery through innovative technologies and its commitment to research and development. However, specific recent developments or changes in the company's strategic direction are not available from the provided data.

Revenue

In Q2FY26, Zim Laboratories Ltd reported a total income of ₹90.75 crores. This represents a 23.9% increase from the previous quarter (Q1FY26), where the total income was ₹73.23 crores. Comparing year-over-year (YoY) performance, the total income saw a slight decrease of 2.9% from Q2FY25, which had a total income of ₹93.46 crores. These figures indicate fluctuations in revenue, reflecting variations in sales or other income over the periods analyzed.

Profitability

For Q2FY26, Zim Laboratories Ltd recorded a loss with a Profit Before Tax (PBT) of ₹-0.34 crores. This marks an improvement from Q1FY26, where the PBT stood at ₹-2.43 crores, showing a quarter-over-quarter (QoQ) positive change of 86.0%. However, when compared to Q2FY25, which reported a PBT of ₹2.96 crores, the year-over-year (YoY) change reflects a decrease of 111.5%. The company also reported a Profit After Tax (PAT) of ₹-0.42 crores in Q2FY26, improving from a PAT of ₹-1.87 crores in Q1FY26. Year-over-year, the PAT declined by 117.6% compared to Q2FY25, where the PAT was ₹2.38 crores. Earnings per Share (EPS) for Q2FY26 were ₹-0.09, showing a sequential improvement from ₹-0.38 in Q1FY26 but a decline from ₹0.49 in Q2FY25.

Operating Metrics

Zim Laboratories Ltd's total expenses for Q2FY26 were ₹91.10 crores, reflecting a 20.4% increase from the previous quarter (Q1FY26), where expenses were ₹75.66 crores. When compared to the same quarter the previous year (Q2FY25), the expenses rose slightly by 0.7% from ₹90.50 crores. The tax expense for Q2FY26 was ₹0.08 crores, a significant change from Q1FY26, which had a tax benefit of ₹-0.56 crores. Year-over-year, there was an 86.2% decrease in tax expense from Q2FY25 when the tax was ₹0.58 crores. These metrics highlight the company's operational cost structure and tax obligations over the quarters analyzed.